A biofunctionalizable ink platform composed of catechol-modified chitosan and reduced graphene oxide/platinum nanocomposite.

We present an ink platform for a printable polymer-graphene nanocomposite that is intended for the development of modular biosensors. The ink consists of catechol-modified chitosan and reduced graphene oxide decorated with platinum nanoparticles (rGO-Pt). We modified the chitosan with catechol groups, in order to obtain adhesive properties and improve solubility.

Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice.

Objectives: To determine, in a chronic dosing study, the oral toxicity potential of the test substances, enclomiphene citrate (ENC) and zuclomiphene citrate (ZUC), when administered to male mice by oral gavage.

Materials And Methods: Mice were divided into five treatment groups. Group I, placebo; Group II, 40 mg/kg body weight/day ENC; Group III, 4 mg/kg/day ENC; Group IV, 40 mg/kg/day ZUC; Group V, 4 mg/kg/day ZUC.

[Real self and ideal self of pregnant and postpartum women with symptoms of perinatal depression].

Aims: To assess real self and ideal self in pregnant and postpartum women with symptoms of perinatal depression in the area of psychological needs and topical scales.

Methods: The study involved 239 pregnant women whose gestational age ranged between 32 and 40 weeks, and 105 postpartum women (2 to 5 days after childbirth). The Edinburgh Postnatal Depression Scale questionnaire was used as a screening test for antenatal and postnatal depressive symptoms.

Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.

Objectives: To determine the pharmacodynamic (PD) profile of serum total testosterone levels (TT) and luteinizing hormone (LH) in men with secondary hypogonadism following initial and chronic daily oral doses of enclomiphene citrate in comparison to transdermal testosterone. To determine the effects of daily oral doses of enclomiphene citrate (Androxal®) in comparison to transdermal testosterone on other hormones and markers in men with secondary hypogonadism.

Patients And Methods: This was a randomized, single blind, two-center phase II study to evaluate three different doses of enclomiphene citrate (6.

Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance.

Telapristone is a selective progesterone antagonist that is being developed for the long-term treatment of symptoms associated with endometriosis and uterine fibroids. The population pharmacokinetics of telapristone (CDB-4124) and CDB-4453 was investigated using nonlinear mixed-effects modeling. Data from two clinical studies (n = 32) were included in the analysis.